ライフサイエンスコーパス: DDS

1 DDS (0-39 pts.), ECD status (+ or -), and preservation t

2 DDS and ECD are determined by a calculation of risk from

3 DDS identified a subgroup of ECD- kidneys, those with DD

4 DDS is inherited in an autosomal dominant fashion, imply

5 DDS is untreatable in reproductive medicine.

6 DDS mutations cluster predominantly in zinc fingers (ZF)

7 DDS was superior to ECD status and RI in its correlation

8 DDS was the best predictor of outcome after deceased don

9 DDS-responsive and several DDS-NO-responsive TCCs expres

10 The Diabetes Distress Scale-17 (DDS-17) is a common measure of diabetes distress.

11 based MCID values for the total DDS-17 and 4 DDS-17 subscales, calculated using the standard error of

12 ) was calculated from home foods only, and a DDS >/=4 constituted minimum dietary diversity (MDD).

13 alyze vastly different analytes comprising a DDS.

14 fter intravitreal delivery or release from a DDS are also reviewed.

15 rgo over the particle size distribution of a DDS by using one integrated method.

16 of recent advances in mechanically activated DDS.

17 vantageous properties for designing advanced DDS including biocompatibility, gelation properties and/

18 d = 0.36 [95% CI, 0.12-0.59]; P = .003) and DDS (F1, 245 = 9.06, Cohen d = 0.37 [95% CI, 0.13-0.60];

19 To conclude, DDS and DDS-NO interact with a number of HLA molecules to activa

20 Thus, DDS- and DDS-NO-specific CD8+ T-cell clones (TCCs) were generated

21 ssociated with PTB, LBW, and fetal loss, and DDS was inversely associated with SGA.

22 equacy were mostly obtained when both SR and DDS were maximal.

23 Overall, light-activated nanomedicines and DDSs are expected to provide more effective therapies ag

24 tide as a targeting moiety in the anticancer DDS substantially enhanced the efficacy of chemotherapy,

25 ice and wild-type mice after 12 weeks of AOM/DDS exposure.

26 ed immunosuppression using biomaterial-based DDS represents an encouraging approach to enhance graft

27 This liquid metal-based DDS with fusible and degradable behaviour under physiolo

28 an distribution of a gold nanoparticle-based DDS containing both a passive and active targeting moiet

29 The interaction between DDS and MMS was tested using a generalized estimating eq

30 ith intravitreal injections of 400-mug Brimo DDS (n = 154) or sham procedure (n = 156) in the study e

31 ltiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated.

32 om baseline was 4.09 (0.15) mm(2) with Brimo DDS (n = 49) versus 4.52 (0.15) mm(2) with sham (n = 46)

33 y endpoint) was 3.24 (0.13) mm(2) with Brimo DDS (n = 84) versus 3.48 (0.13) mm(2) with sham (n = 91)

34 , a reduction of 0.43 mm(2) (10%) with Brimo DDS compared with sham (P = 0.033).

35 ), a reduction of 0.25 mm(2) (7%) with Brimo DDS compared with sham (P = 0.150).

36 ssed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24).

37 that CD4+ and CD8+ T cells are activated by DDS and its nitroso metabolite (nitroso dapsone [DDS-NO]

38 S compared with IFA on LBW were estimated by DDS.

39 However, activation of certain DDS-NO-responsive CD8+ TCCs was inhibited with HLA class

40 also be achieved with these renal clearable DDSs, which might also be applied to improve the precisi

41 This study was designed to compare DDS, ECD status, and RI as predictors of outcome after d

42 A total of 248 individuals with complete DDS-17 data were included (mean [SD] age, 67.4 [8.3] yea

43 To conclude, DDS and DDS-NO interact with a number of HLA molecules t

44 As a result, current DDSs can be tagged as dubbed "Smart Biomaterials" since

45 of drug-resistant strains; however, dapsone (DDS) resistance continues to be reported.

46 Today, dapsone (DDS) resistance has led to fear of leprosy in more unfor

47 HLA-B*13:01 is associated with dapsone (DDS)-induced hypersensitivity, and it has been shown tha

48 and its nitroso metabolite (nitroso dapsone [DDS-NO]).

49 The effect was greatest at the lowest DDS [DDS= 1, RR LBW: 0.86 (0.81, 0.91)] and decreased at high

50 improving existing treatments and developing DDS for novel therapies.

51 e is a firm rationale for further developing DDS for local therapeutic delivery to GBM and other brai

52 tion method based on dichlorodimethylsilane (DDS)-Tween-20 for in vitro single-molecule studies, whic

53 e associated with Wilms' tumor, Denys Drash (DDS), and Frasier syndromes.

54 effect of MMS on LBW were estimated at each DDS.

55 However, the facile synthesis of effective DDSs remains a challenge.

56 ls can lead to obtaining much more efficient DDSs for the treatment of age-related macular degenerati

57 Scientists have engineered DDS for endothelial delivery through the modification of

58 on empirical methods to design and evaluate DDS composition and geometry, as well as dosing regimens

59 Existing DDSs have already positively influenced patient acceptab

60 This simply fabricated DDS may find applications in high effective cancer thera

61 s from underrepresented groups increased for DDS and DMD, PharmD (applicants, from 9045 of 71 966 to

62 UC and EPICC groups remained significant for DDS score (F1, 245 = 8.94, Cohen d = 0.36 [95% CI, 0.12-

63 DDS.DWI may be a useful diagnostic tool for DDS in patients with end-stage renal disease.

64 The MCID value for DDS-17 was 0.25 and MCID values for the 4 distress subsc

65 4 and this difference could be harnessed for DDSs to release encapsulated drugs specifically to these

66 Furthermore, DDS development can be optimized by implementing mathema

67 g innovations for developing next-generation DDS that can enable clinical translation of intra-articu

68 mutations, a heteroduplex DDS M. leprae (HD-DDS-ML) assay was developed for the simultaneous detecti

69 The HD-DDS-ML assay detected as few as 100 M. leprae organisms

70 The HD-DDS-ML assay provides a new tool for the simultaneous de

71 fected with 14 separate strains using the HD-DDS-ML assay.

72 Herein, DDS was chemically conjugated with five phytochemicals i

73 Based on these mutations, a heteroduplex DDS M. leprae (HD-DDS-ML) assay was developed for the si

74 zed to receive either a GA (control) or a HF-DDS graft (test).

75 this investigation, the tissue engineered HF-DDS graft was safe and capable of generating keratinized

76 man fibroblast-derived dermal substitute (HF-DDS), compared to a gingival autograft (GA) consisting o

77 ratinized tissue and shrank less than the HF-DDS graft, but the test graft generated tissue that appe

78 Higher DDS was associated with lower risk of SGA (RR highest co

79 tunting (RR 0.93; 95% CI 0.87, 1.00), higher DDS (MD 0.17; 95% CI 0.06, 0.29), had 0.07 (95% CI 0.01,

80 was born in Toronto, Canada and received his DDS degree from the University of Toronto in 1957.

81 f HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and l

82 However, DDS components can vary greatly, requiring numerous anal

83 tability of a hyaluronic acid-based hydrogel DDS under forced alkaline and enzymatic in vitro degrada

84 An ideal DDS must deliver drugs to the target region at therapeut

85 We were also interested to see if DDS or ECD could identify kidneys most likely to benefit

86 pment of more efficient LNP DDSs and improve DDS selection methodologies overall.

87 One-log bacilli cells in DDS-resistant infected mice footpads decreased by the DP

88 Baseline to postintervention changes in DDS-17 and its 4 subscale scores were grouped into 3 cat

89 ffect" in the pathogenesis of brain edema in DDS.DWI may be a useful diagnostic tool for DDS in patie

90 Improvements in DDS scores were modest.

91 bsolute increase and the rate of increase in DDS clients aged 3 to 5 years with autism were higher th

92 or BMD, were unrelated to screw loosening in DDS.

93 years with autism were higher than those in DDS clients of the same ages with any eligible condition

94 monly suitable for characterizing individual DDS properties, but do not allow determination of severa

95 ozygosity for the Wt1tmT396 mutation induces DDS in heterozygous and chimeric (Wt1tmT396/+<-->+/+) mi

96 and empirical methods can offer insight into DDS pharmacokinetics and pharmacodynamics.

97 tool to systematically evaluate intravaginal DDS performance as a function of drug diffusion, reactio

98 ecutive patients who underwent 2- or 3-level DDS for spondylosis, recurrent disc herniations, or low-

99 continued development of more efficient LNP DDSs and improve DDS selection methodologies overall.

100 Our findings reveal that LNP DDSs induce significant changes in the structures and st

101 des a summary of recently investigated local DDS with different mechanisms of action such as on-deman

102 The effect was greatest at the lowest DDS [DDS= 1, RR LBW: 0.86 (0.81, 0.91)] and decreased at

103 ility to address the problems that have made DDSs unsuccessful in the past.

104 Elizabeth Dianne Rekow, BSME, MSME, MBA, DDS, MS, Certificate in Orthodontics, and PhD, was a den

105 Median DDS was 3.0 (IQR: 2.5-3.5).

106 The median DDS was 3 (interquartile range: 2, 4), and 18.6% of preg

107 psulated hydrophobic dyes were used as model DDSs.

108 A myriad of nano DDSs have been explored to be pH-responsive, including l

109 prodrugs from drug-loaded pH-sensitive nano DDSs have been applied in research on anticancer therapy

110 lopment and application of pH-sensitive nano DDSs.

111 ize, compare and contrast the different nano-DDS described in the literature so far, and compare thei

112 egard, nanoscale drug delivery systems (Nano-DDS) have led to the expectation that they will eventual

113 iocin nano-sized drug delivery systems (Nano-DDS).

114 e highlight the importance of tailoring nano-DDS to address bacteriocin limitations, the successes an

115 Thus, combining bacteriocins with nano-DDS may be useful in overcoming these drawbacks and ther

116 Pre-clinical development for nanocarrier DDS has focused on improving existing treatments and dev

117 ere are three key features of this nanoscale DDS: (a) use of functionalized SWNTs as a biocompatible

118 n individuals in prey aggregations (negative DDS, the preferential selection by predators of spatiall

119 Both positive and negative DDS on prey groups have been documented in nature but th

120 tial challenges for commercialization of new DDS are presented.

121 tive or functional compounds, makes this new DDS suitable for a wide range of therapeutic or imaging

122 , 7, and 10-fold, respectively, for the 5 nm DDS over 30 nm one.

123 artificial prey (positive, negative, and non-DDS) are displayed through different combinations of the

124 d (NL) nanoparticle drug delivery system (NP-DDS) to encapsulate 6-shogaol and undertake its controll

125 e for infertile patients suffering from Odf2-DDS.

126 report for the first time a new type of Odf2-DDS in heterozygous mutant Odf2(+/-) mice.

127 matically covers the most recent advances of DDS applicable by topical instillation, that have shown

128 There was no direct association of DDS-17 MCID improvement (beta = -0.25; 95% CI, -0.59 to

129 methods were used to assess associations of DDS and PDQS with PTB, SGA, LBW, and fetal loss.

130 ria and glomerulosclerosis characteristic of DDS patients.

131 workflow to guide preclinical development of DDS-based intra-articular DMOAD therapies.

132 Numerous forms of DDS on artificial prey (positive, negative, and non-DDS)

133 DPC4 could be used in place of DDS in MDT, evidenced from in vivo antileprosy activity

134 The estimated prevalence of DDS clients aged 3 to 5 years with autism increased for

135 eral limitations for clinical translation of DDS.

136 egardless of the drug, animal model, type of DDS used, or duration of the study.

137 Depending on the type of DDS, polymer material, and preparation method, different

138 pective describe the distinctive features of DDSs and donors concerning their design, synthesis, phot

139 nts were in the MCID improvement category on DDS-17 (63 participants [51.22%] vs 40 participants [32.

140 review combines past and present research on DDS design directed toward the pathological pulmonary en

141 ffector molecules when exposed to DDS and/or DDS-NO.

142 In vitro study reveals that our DDS exhibit excellent properties like biocompatibility,

143 fabricated nanocarrier would be a potential DDS against colorectal cancer cells.

144 y, and load capacity, thus being a promising DDS.

145 The proposed DDS minimizes the uptake of the drug by normal cells and

146 Preclinical models using TAC-releasing DDS have demonstrated high local immunosuppressive effec

147 The relevant DDS can be activated to promote drug release by differen

148 e heavily implicated electrically responsive DDS.

149 n employed in the design of light-responsive DDSs.

150 Among them, pH-responsive DDSs have gained popularity since the pH in the diseased

151 tcomes included the Diabetes Distress Scale (DDS), Morisky Medication Adherence Scale, and Lorig Self

152 A 7-food group dietary diversity score (DDS) was calculated from home foods only, and a DDS >/=4

153 A 10-item dietary diversity score (DDS) was created by summing the number of food groups co

154 um, iron, and zinc and diet diversity score (DDS) were used to assess diet quality.

155 n outcome was child dietary diversity score (DDS, range 0 to 7).

156 The deceased donor score (DDS), expanded criteria donor (ECD) definition, and resi

157 Dietary diversity scores (DDS; range: 0-10) were computed as the number of food gr

158 0.81, 0.91)] and decreased at higher scores [DDS = 7, RR: 0.92 (0.84, 1.00)].

159 have been developed to prepare pH-sensitive DDSs, including introduction of a variety of pH-sensitiv

160 fornia Department of Developmental Services (DDS) have been interpreted as supporting the hypothesis

161 DDS-responsive and several DDS-NO-responsive TCCs expressing a variety of TCR seque

162 Slavkin, DDS, the 22nd president of the American Association for

163 orption (DVS) and dynamic dewpoint sorption (DDS) techniques.

164 ork to engineer such degenerate dark spaces (DDS), protected from decoherence by the environment.

165 e of decapitated and decaudated spermatozoa (DDS), whose semen contains abnormal spermatozoa with tai

166 loosening in Dynesys dynamic stabilization (DDS).

167 rized synthesis strategies of pH-stimulating DDSs, illustrated commonly used and recently developed n

168 n edema in dialysis disequilibrium syndrome (DDS) was investigated by diffusion-weighted magnetic res

169 Denys-Drash syndrome (DDS) is caused by dominant mutations of the Wilms' tumou

170 ncluding Wilms tumors, Denys-Drash syndrome (DDS), Frasier syndrome (FS) and WAGR syndrome (Wilms tum

171 , including dopamine dysregulation syndrome (DDS) and punding.

172 y-onset renal failure (Denys-Drash syndrome [DDS]).

173 ved potential the ability of the synthesized DDS in the inhibition of colorectal cancer cells.

174 ims to develop a novel drug delivery system (DDS) based on Chitosan (CS), polyamidoamine (PAMAM G4),

175 )-based tumor-targeted drug delivery system (DDS) has been developed, which consists of a functionali

176 a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitiga

177 ized nanoparticle (NP) drug delivery system (DDS) to facilitate improved delivery of systemic treatme

178 d photoresponsive dual drug delivery system (DDS) to release two different anticancer drugs (caffeic

179 organs, we proposed a drug delivery system (DDS) with specific targeting ligands for cancer cells.

180 develop a new kind of drug delivery system (DDS), namely, CB[7]-VH4127, with maintained binding affi

181 acting/extended release (LA/ER) DD Systems (DDS) currently in development show considerable promise,

182 ch in intra-articular drug delivery systems (DDS) and two decades of advances in disease-modifying os

183 New drug delivery systems (DDS) are necessary to overcome the bioavailability and t

184 Novel therapies and drug delivery systems (DDS) emphasis on localized, personalized, triggered, and

185 Drug delivery systems (DDS) enhance drug delivery for treating gynecological ca

186 Advanced drug delivery systems (DDS) enhance treatment efficacy of different therapeutic

187 ades, a vast array of drug delivery systems (DDS) have been developed for the local treatment of GBM,

188 ral decades, numerous drug delivery systems (DDS) have been developed in order to improve drug bioava

189 ing biomaterial-based drug delivery systems (DDS) have been developed.

190 Drug delivery systems (DDS) have been engineered to target therapeutics to the

191 riety of intravaginal drug delivery systems (DDS) including creams, gels, suppositories, tablets, rin

192 mitochondria-targeted drug delivery systems (DDS).

193 e-specific controlled drug delivery systems (DDSs) and has encouraged their rapid development in rece

194 for the assessment of drug-delivery systems (DDSs) are commonly suitable for characterizing individua

195 LNPs are distinctive drug delivery systems (DDSs) because of their ability to target specific cells,

196 nvironment-responsive drug delivery systems (DDSs) can achieve targeted drug delivery, reduce drug si

197 his problem, numerous drug delivery systems (DDSs) have been developed.

198 in the development of drug delivery systems (DDSs) have been the short half-life, poor bioavailabilit

199 Drug delivery systems (DDSs) have demonstrated effectiveness in enhancing bioav

200 particle (AuNP)-based drug delivery systems (DDSs) in the delivery of doxorubicin (DOX).

201 vely or actively from drug delivery systems (DDSs) or bioactive donors.

202 ed by newly developed drug delivery systems (DDSs), side effects of cancer chemotherapy could be redu

203 Among drug delivery systems (DDSs), smart nanocarriers that respond to specific stimu

204 f these newly emerged drug delivery systems (DDSs), which enable drugs to rapidly penetrate into the

205 ave been explored for drug delivery systems (DDSs).

206 The LHRH receptor targeting DDS did not show in vivo pituitary toxicity and did not

207 uously been proven that this tumor-targeting DDS works exactly as designed and shows high potency tow

208 Recently, it has been determined that DDS-resistant strains contain missense mutations in codo

209 The DDS data do not show any recent decrease in autism in Ca

210 The DDS data do not support the hypothesis that exposure to

211 The DDS-Tween-20 surface was simple and inexpensive to prepa

212 sion of basic oral science education for the DDS curriculum was established at the University at Buff

213 y important difference (MCID) values for the DDS-17.

214 y the DPC4, and no bacilli were found in the DDS-sensitive mice hind pads.

215 ism among children with active status in the DDS.

216 autism who were active status clients of the DDS from January 1, 1995, through March 31, 2007.

217 Most of the DDS have been developed using natural or synthetic polym

218 g the pharmacokinetic (PK) parameters of the DDS is essential to overcome these challenges.

219 The current review focuses on the DDS technologies, critical challenges, opportunities, st

220 vement or worsening of more than 0.25 on the DDS-17 was quantitatively significant and patients in th

221 he fractional quantum Hall effect, where the DDS basis is isomorphic to a set of degenerate Laughlin

222 ion of diagnostic in vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous

223 fficient accumulation and penetration of the DDSs into the tumor tissue.

224 anding of the underlying mechanisms of these DDS approaches is expected to further contribute to this

225 nd recently developed nanocarriers for these DDSs and covered their potential in different biomedical

226 To prove the efficacy of this DDS, three fluorescent and fluorogenic molecular probes

227 onstrate the translational potential of this DDS, we delivered niclosamide (NEN), an S100a4 inhibitor

228 We examined three DDS associated mutations in ZF2 of human WT1 where the n

229 Thus, DDS- and DDS-NO-specific CD8+ T-cell clones (TCCs) were

230 d secrete effector molecules when exposed to DDS and/or DDS-NO.

231 d separated an array of analytes relevant to DDS.

232 on of M. leprae and of its susceptibility to DDS from a single specimen.

233 on of M. leprae and of its susceptibility to DDS.

234 distribution-based MCID values for the total DDS-17 and 4 DDS-17 subscales, calculated using the stan

235 ivated therapies, especially light-triggered DDSs, relying on photoisomerization, photo-cross-linking

236 While the two DDSs themselves had comparable tumor targeting, we found

237 I stress the importance of understanding DDS on prey groups given the recent emergence of these s

238 Interestingly a mutation associated with DDS enhanced both -KTS WT1 binding to U2AF65 and splicin

239 The increased Dapp associated with DDS indicates that brain extracellular water increases a

240 was inhibited with HLA class-II block, with DDS-NO binding to HLA-DQB1*05:01.

241 skin and demonstrated a 93% correlation with DDS susceptibility as determined by both DNA sequencing

242 , were greatest in the group of kidneys with DDS > or = 20 pts.

243 nitive evidence linking these mutations with DDS resistance in M. leprae has been obtained.

244 ified a subgroup of ECD- kidneys, those with DDS > or = 20 pts, that functioned significantly below e